Please assess the completion status of the following clinical trial:

Trial Title: ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histology confirmed diagnosis of extremities high grade osteosarcoma~* Age ≤ 40 years~* Localized disease or presence of skip metastasis~* Hepatic, renal and bone marrow normal function~* LVEF \> 50%~* No previous surgery and/ or chemotheraputic osteosarcoma treatments,~* No more than 4 weeks interval between histological diagnosis and start of chemotherapy~* Informed consent to the study participation obtained.~Exclusion Criteria:~* Presence of metastases other than skip metastases~* Periosteal Osteosarcoma, parostal osteosarcoma, secondary osteosarcoma,~* Medical contra-indication to the drugs foreseen in the protocol,~* Subject is pregnant or breast feeding~* Mental or social conditions that can compromise a correct adherence to the protocol and its procedures

- Gender: ALL
- Minimum Age: None
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Mifamurtide arm (Type: EXPERIMENTAL): Chemotherapy for patients who over express ABCB1/P-glycoprotein (methotrexate, cisplatinum, doxorubicine, ifosfamide + mifamurtide)
- 3 drugs arm (Type: OTHER): High grade osteosarcoma treatment for patients who do not over express ABCB1/P-glycoprotein

Based on this trial design, predict the completion outcome and termination type (if applicable).